- $74.08m
- $60.52m
- $58.44m
Brief: Lensar Reports Fourth Quarter And Full Year 2022 Results And Provides Business Update
Lensar Inc Expected To Post A Loss Of 25 Cents A Share: Earnings Preview
Lensar Inc Expected To Post A Loss Of 25 Cents A Share: Earnings Preview
Brief: Lensar Announces Preliminary Fourth Quarter And Full Year 2022 Results
Lensar Inc Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Lensar Reports Q3 Loss of $0.39 Per Share
Lensar Inc Expected To Post A Loss Of 62 Cents A Share: Earnings Preview
Lensar Inc Expected To Post A Loss Of 62 Cents A Share: Earnings Preview
Brief: Lensar Announces Application For Certification Of The Ally™ Adaptive Cataract Treatment System In The EU
Brief: Lensar Inc - first patients treated with Lensar’S® Ally™ adaptive cataract treatment system
Lensar Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Lensar Reports Second Quarter 2022 Financial Results
Brief: LENSAR Expects To Place 8-12 Ally Systems In Controlled And Targeted Initial Launch
U.S. STOCKS ON THE MOVE-Choice Hotels International Inc, Campbell Soup, Day One Biopharmaceuticals
U.S. STOCKS ON THE MOVE-IMAX Corp, Volta, Ekso Bionics Holdings
U.S. STOCKS ON THE MOVE-Electric Last Mile Solutions, bluebird bio, Duke Realty Corp
LENSAR jumps as cataract surgery system wins FDA approval
Brief: Lensar Receives U.S. FDA Clearance Of Ally Adaptive Cataract Treatment System
Lensar Inc Reports Results For The Quarter Ended In March: Earnings Summary